Our Mission is to discover and develop gene therapy solutions that directly target mitochondrial dysfunction for prevalent neurodegenerative diseases.

Our Science is based on the knowledge that mitochondrial dysfunction is implicated in the pathophysiology of many neurodegenerative diseases. 

Our Technologies have applications for multiple neurodegenerative diseases including dry age-related macular degeneration (dry AMD), glaucoma, Alzheimer’s Disease, Parkinson’s Disease and Motor Neuron Disease.

Our Focus is on our lead asset VZ-103, an AAV based gene therapy which shows promise for dry AMD.